1. Home
  2. HAFN vs LEGN Comparison

HAFN vs LEGN Comparison

Compare HAFN & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Hafnia Limited

HAFN

Hafnia Limited

N/A

Current Price

$8.83

Market Cap

5.5B

Sector

N/A

ML Signal

N/A

Logo Legend Biotech Corporation

LEGN

Legend Biotech Corporation

N/A

Current Price

$15.25

Market Cap

4.6B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
HAFN
LEGN
Founded
2012
2014
Country
Singapore
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.5B
4.6B
IPO Year
2020
2020

Fundamental Metrics

Financial Performance
Metric
HAFN
LEGN
Price
$8.83
$15.25
Analyst Decision
Buy
Buy
Analyst Count
2
14
Target Price
$11.50
★ $40.93
AVG Volume (30 Days)
2.0M
★ 2.5M
Earning Date
11-18-2026
11-10-2026
Dividend Yield
★ 12.37%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$38.78
Revenue Next Year
N/A
$17.61
P/E Ratio
$11.39
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.17
$15.73
52 Week High
$11.12
$37.50

Technical Indicators

Market Signals
Indicator
HAFN
LEGN
Relative Strength Index (RSI) 36.53 31.52
Support Level $8.54 N/A
Resistance Level $9.06 $19.92
Average True Range (ATR) 0.36 1.39
MACD -0.12 -0.73
Stochastic Oscillator 5.97 0.49

Price Performance

Historical Comparison
HAFN
LEGN

About HAFN Hafnia Limited

Hafnia Ltd is one of the tanker owners, transporting oil, oil products and chemicals for national and international oil companies, chemical companies, as well as trading and utility companies. As owners and operators of around 200 vessels, It offers a fully integrated shipping platform, including technical management, commercial and chartering services, pool management, and a large-scale bunker procurement desk. Company manages it's business through the following reporting segments: LR2 tankers, LR1 tankers, MR tankers, Handy tankers.

About LEGN Legend Biotech Corporation

Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.

Share on Social Networks: